irinotecan / Generic mfg.  >>  Phase 1
Welcome,         Profile    Billing    Logout  

101 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
irinotecan / Generic mfg.
KEYNOTE-651, NCT03374254: Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651)

Checkmark Initial data from KEYNOTE-651 combination trial with Mektovi in metastatic CRC
Sep 2019 - Sep 2019: Initial data from KEYNOTE-651 combination trial with Mektovi in metastatic CRC
Completed
1b
114
Canada, US
Pembrolizumab, MK-3475, Binimetinib, MEK162, ARRY-162, ARRY-438162, Oxaliplatin, Leucovorin, calcium folinate, 5-Fluorouracil [5-FU], Irinotecan
Merck Sharp & Dohme LLC, Array BioPharma
Metastatic Colorectal Cancer
09/21
07/23
NCT04689347: 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.

Recruiting
1b
18
Europe
Bevacizumab, Irinotecan, Leucovorin, 5Fluorouracil, Temozolomide
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Metastatic Colorectal Cancer
12/22
01/23
CAPAFOUR, NCT04990037: A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

Completed
1b
25
Europe
CAN04, Nadunolimab, FOLFIRINOX
Cantargia AB
Metastatic Pancreatic Ductal Adenocarcinoma
05/23
06/23
COSMIC-021, NCT03170960: Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Checkmark Presentation of data from COSMIC-021 trial in combination with atezolizumab for HNSCC at SITC 2022
Dec 2021 - Nov 2022: Presentation of data from COSMIC-021 trial in combination with atezolizumab for HNSCC at SITC 2022
Checkmark Data from additional cohorts in combination with Tecentriq for solid tumors
Jul 2022 - Jul 2022: Data from additional cohorts in combination with Tecentriq for solid tumors
Checkmark P1b results in combination with Tecentriq for metastatic NSCLC at ASCO 2022 based on COSMIC-021 trial
More
Active, not recruiting
1b
1732
Europe, US, RoW
cabozantinib, Cabometyx, XL184, atezolizumab, Tecentriq
Exelixis
Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer
07/23
08/24
NCT05557851: Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas

Recruiting
1b
36
RoW
Minnelide
Minneamrita Therapeutics LLC
Metastatic Adenocarcinoma of the Pancreas
06/24
12/24
ACTRN12614000552684: A Phase 1 study of Temozolomide, Irinotecan, and O6BG (O6-Benzylguanine) for Children with Recurrent or Resistant Neuroblastoma

Not yet recruiting
1
24
 
The Sydney Children's Hospitals Network, The Kids Cancer Project will provide funding for the manufacture of the O6BG drug.
Recurrent Neuroblastoma, Resistant neuroblastoma
 
 
ACTRN12624000455561: Safety and efficacy of faecal transplant and chemotherapy in the management of pancreatic cancer

Not yet recruiting
1
60
 
Central Adelaide Local Health Network (CALHN), Department of Health and Aged Care - Medical Research Future Fund (MRFF)
non-resectable pancreatic cancer
 
 
NCT00045201: Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

Active, not recruiting
1
60
US
Erlotinib Hydrochloride, CP 358, CP-358, Cp-358,774, CP358, OSI 774, OSI-774, OSI774, Tarceva, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, CPT11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U 101440E, U-101440E, U101440E
National Cancer Institute (NCI)
Adult Solid Neoplasm
09/13
08/25
NCT01835041: CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

Completed
1
21
US
6,8-bis(benzylthio)octanoic acid, alpha-lipoic acid analogue CPI-613, CPI-613, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, laboratory biomarker analysis
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
02/17
03/23
NCT03279237: A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers

Active, not recruiting
1
25
US
Irinotecan, Camptosar, Oxaliplatin, Eloxatin, Leucovorin, 5-Fluorouracil, Efudex, Paclitaxel, Abraxane, Radiation Therapy, Carboplatin
Massachusetts General Hospital, National Cancer Institute (NCI)
GastroEsophageal Cancer
11/18
09/23
ChiCTR1800015223: Phase Ib clinical study evaluated the safety, tolerability, and pharmacokinetic characteristics of human recombinant interleukin-1 receptor antagonist in cancer patients received FOLFIRI chemotherapy

Recruiting
1
12
 
C0 period: GR007 90 mg, i.m., single dose; C1 period: GR007 90 mg, i.m., single dose before FOLFIRI chemotherapy ;C0 period: GR007 90 mg, i.m., dosing for 3 consecutive days; C1 period: GR007 90 mg, i.m., dosing for 3 consecutive days before FOLFIRI chemotherapy ;C0 period: GR007 90 mg, i.m., dosing for 5 consecutive days; C1 period: GR007 90 mg, i.m., dosing for 5 consecutive days before FOLFIRI chemotherapy ;C0 period: GR007 90 mg, i.m., dosing for 8 consecutive days; C1 period: GR007 90 mg, i.m., dosing for 8 consecutive days before FOLFIRI chemotherapy
Shanghai Orient Hospital; Shanghai Orient Hospital, General Regeneratives(Shanghai) Limited
cancer
 
 
NCT02085148 / 2013-003579-36: A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy

Completed
1
62
Europe
Regorafenib (BAY73-4506), Vincristine (Cellcristin®), Irinotecan (Irinotecan Cell pharm®)
Bayer
Pediatric Oncology
05/19
03/24
Phase I trial of JY025, ChiCTR1900022387: Phase Ia/Ib study for Saftey, Tolerability, Pharmacokinetics, pharmacodynamics and efficacy of recombinant human anti-VEGFR-2 antibody(JY025) in patients with advanced, recurrent or metastatic solid tumor

Recruiting
1
63
 
JY025, 4mg/kg, intravenous infusion ;JY025, 8mg/kg, intravenous infusion ;JY025,12mg/kg, intravenous infusion ;JY025,16mg/kg, intravenous infusion ;JY025,20mg/kg, intravenous infusion ;JY025,24mg/kg, intravenous infusion ;JY025, paclitaxel, intravenous infusion ;JY025, Irinotecan, 5-Fluorouracil, Folinic Acid, intravenous infusion ;JY025, intravenous infusion, best supportive care
307th Hospital of Chinese People's Liberation Army; Eastern Biotech Co., Ltd., Self-Finance
Advanced Solid Tumor
 
 
2019-002931-27: A Phase 1b/2 Study of Abemaciclib Plus Chemotherapy and/or Chemoimmunotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors

Not yet recruiting
1
60
Europe
Abemaciclib, Verzenios, Temozolomide Accord, Temozolomide Sun, Temodal, Irinotecan Bendalis, Campto, Irinotecan Kabi, Irinotecan, Verzenios, NA, Film-coated tablet, Capsule, Concentrate for solution for infusion, Verzenios, Temozolomide Accord, Temozolomide Sun, Temodal, Irinotecan Bendalis, Campto, Irinotecan Kabi, Irinotecan cell pharm®, Temodmedac, Temozolomide Hexal, Temozolomide Sandoz, Temozolomide Teva
Eli Lilly and Company, ELI LILLY & COMPANY, LILLY CORPORATE CENTER, Eli Lilly and Company
Pediatric and Young Adult Patients Relapsed/Refractory Solid Tumors, Pediatric and Young Adult Patients Solid Tumors, Diseases [C] - Cancer [C04]
 
 
NIPOX, NCT03253133: Assessing Safety of in Peritoneal Carcinomatosis of CRC

Completed
1
19
Europe
Oxaliplatin, LV5FU or Folfiri, Oxycodone
Institut du Cancer de Montpellier - Val d'Aurelle
Colorectal Cancer
10/20
04/23
ONO-4578-04, NCT06538207: An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Active, not recruiting
1
46
Japan
ONO-4578, ONO-4538, Nivolumab, Oxaliplatin, Levofolinate, Irinotecan, Fluorouracil, Gemcitabine, Nab-Paclitaxel
Ono Pharmaceutical Co. Ltd
Metastatic Pancreatic Cancer
10/24
11/24
NCT06532344: An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Active, not recruiting
1
32
Japan
ONO-7913, Magrolimab, ONO-4538, Nivolumab, Oxaliplatin, Levofolinate, Irinotecan, Fluorouracil
Ono Pharmaceutical Co. Ltd
Metastatic Pancreatic Cancer
05/25
05/25
ADVL1615, NCT03323034 / 2019-002934-35: Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Active, not recruiting
1
30
US
Irinotecan, Pevonedistat, MLN4924, Nedd8-Activating Enzyme Inhibitor MLN4924, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
Children's Oncology Group, National Cancer Institute (NCI)
Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm
09/21
09/24
alloSHRINK, NCT03692429: - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

Checkmark From alloSHRINK trial for mCRC
Jul 2019 - Jul 2019: From alloSHRINK trial for mCRC
Hourglass Jul 2017 - Dec 2017 : Initiation of allogeneic P1 trial in cancer (unspecified tumor type)
: Topline data from alloSHRINK trial in colorectal
: Topline data from alloSHRINK trial in colorectal
More
Recruiting
1
49
Europe, US
CYAD-101, FOLFOX, FOLFIRI
Celyad Oncology SA
Unresectable Metastatic Colorectal Cancer
11/21
02/36
Proton-PANC, NCT03885284: Study of Proton Therapy in Adjuvant Pancreatic Cancer

Recruiting
1
12
US
mFOLFIRINOX, Proton beam radiation
Georgetown University
Resected Pancreatic Adenocarcinoma
12/21
12/21
NCT04689100: Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor

Recruiting
1
259
RoW
JMT101, FOLFIRI(Irinotecan, Leucovorin Calcium, and Fluorouracil); mFOLFOX6((Oxaliplatin, Leucovorin Calcium, and Fluorouracil);, FOLFIRI; mFOLFOX6; Irinotecan;
Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Solid Tumor
12/21
06/22
NCT02975882: Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Active, not recruiting
1
33
US
Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U-101440E, Laboratory Biomarker Analysis, Pharmacological Study, Sirolimus Albumin-bound Nanoparticles, ABI-009, Albumin-bound Sirolimus, Fyarro, Nab-Rapamycin, Nab-sirolimus, Nanoparticle Albumin-Bound Rapamycin, Nanoparticle Albumin-bound Sirolimus, Sirolimus Albumin-bound Particles, Sirolimus Protein-bound Particles, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
Children's Oncology Group, National Cancer Institute (NCI)
Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm
03/22
09/24
CITRINO, NCT03250832: Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors

Checkmark Data from CITRINO trial in combination with TSR-033 in advanced solid tumors
Nov 2018 - Nov 2018: Data from CITRINO trial in combination with TSR-033 in advanced solid tumors
Completed
1
111
Europe, US
TSR-033, LAG-3, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
Tesaro, Inc., GlaxoSmithKline
Neoplasms
06/22
02/23
NCT01858168: Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma

Active, not recruiting
1
93
US
Olaparib, AZD2281, Temozolomide, Temodal, SCH52365, Temodar, Irinotecan, Camptosar
Massachusetts General Hospital
Ewing Sarcoma, Rhabdomyosarcoma
11/24
12/24
NCT04074343: TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

Completed
1
20
US
TAS-102, LONSURF, trifluoridine and tipiracil, Irinotecan, CAMPTOSAR, CPT-11
University of California, Irvine, Taiho Pharmaceutical Co., Ltd.
Gastric Adenocarcinoma, GastroEsophageal Cancer
07/21
07/22
NCT05201326: Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma

Recruiting
1
20
RoW
Bevacizumab，Irinotecan and Re-radiotherapy
Ruijin Hospital
Recurrent Glioblastoma
12/22
12/24
NCT02613650: A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers

Completed
1
25
US
MEK162 and mFOLFIRI, Binimetinib
University of Utah, Pfizer
Advanced KRAS Positive Metastatic Colorectal Cancer
11/22
12/22
NCT04292743: Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma

Active, not recruiting
1
19
US
Eryaspase, FOLFIRINOX, 5-fluorouracil, oxaliplatin, Irinotecan, leucovorin
Georgetown University, ERYtech Pharma
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
01/23
07/24
NCT03798626: Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Active, not recruiting
1
167
Europe, Canada, Japan, US, RoW
Gevokizumab, VPM087, Bevacizumab, Modified FOLFOX6, oxaliplatin, leucovorin, 5-fluorouracil, FOLFIRI, irinotecan, leucovorin, 5-fluorouracil, Ramucirumab, Paclitaxel, Cabozantinib
Novartis Pharmaceuticals
Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
03/23
12/24
NCT04425876: A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer

Recruiting
1
74
RoW
Fluzoparib, SHR3162
Jiangsu HengRui Medicine Co., Ltd.
Pancreatic Cancer
03/23
09/23
NCT04612530: PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer

Recruiting
1
18
Europe
Irreversible Electroporation (IRE), Nivolumab, Toll-Like Receptor 9
Amsterdam UMC, location VUmc
Pancreatic Cancer, Metastatic Pancreatic Cancer
04/23
06/23
NCT00576654: Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

Active, not recruiting
1
36
US
Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U-101440E, Laboratory Biomarker Analysis, Pharmacological Study, Veliparib, ABT-888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Hodgkin Lymphoma, Metastatic Malignant Neoplasm, Metastatic Malignant Solid Neoplasm, Non-Hodgkin Lymphoma, Stage III Breast Cancer AJCC v7, Stage III Colon Cancer AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Colon Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Colon Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Colon Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colon Cancer AJCC v7, Stage IV Lung Cancer AJCC v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colon Cancer AJCC v7, Stage IVB Colon Cancer AJCC v7, Triple-Negative Breast Carcinoma, Unresectable Malignant Neoplasm, Unresectable Solid Neoplasm
06/23
06/23
NCT05257993: Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Recruiting
1
24
RoW
JPI-547, modified FOLFIRINOX, Gemcitabine-nab-paclitaxel
Onconic Therapeutics Inc.
Pancreatic Ductal Adenocarcinoma
12/24
12/24
ChiCTR2200063316: Phase IB clinical study on the tolerance, safety and efficacy of darafenib, trametinib combined with irinotecan and cetuximab in advanced colorectal cancer with BRAF mutation

Not yet recruiting
1
18
 
Darafenitumertinib plus iritiniconcetuximab
Sichuan Cancer Hospital; Sichuan Cancer Hospital, None
colorectal cancer
 
 
NCT04135807: Implantable Microdevice In Primary Brain Tumors

Recruiting
1
12
US
Microdevice, Implantable Microdevice
Oliver Jonas, PhD
Grade II Glioma, Grade III Glioma, Grade IV Glioma, Astrocytoma, Oligodendroglioma of Brain, Anaplastic Astrocytoma of Brain, Anaplastic Oligodendroglioma, Glioblastoma
09/23
02/24
NCT05209074: Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

Recruiting
1
16
US
Ivosidenib, mFOLFIRINOX
Case Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Cancer
07/26
12/26
NCT05087992: A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers

Completed
1
13
Europe, Japan, US, RoW
BI 905711, FOLFIRI, Bevacizumab
Boehringer Ingelheim
Gastrointestinal Cancer, Metastatic
10/23
11/23
NCT02013336: Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

Recruiting
1
30
US
MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
South Plains Oncology Consortium
Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma, Osteosarcoma
12/23
12/23
NCT03554707: SGT-53 in Children With Recurrent or Progressive CNS Malignancies

Not yet recruiting
1
6
US
SGT-53, Radiation, Irinotecan, Camptosar, Onivyde, Temozolomide, Temodar, Bevacizumab, Avastin
SynerGene Therapeutics, Inc.
Childhood CNS Tumor
12/23
12/24
PIRATE, NCT04525014: RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors

Terminated
1
2
US
RRx-001, Temozolomide, Irinotecan
EpicentRx, Inc., Texas Children's Cancer Center
Brain Tumor, Recurrent, Brain Tumor, Pediatric, Central Nervous System Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific
07/24
07/24
NCT02192359: Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

Active, not recruiting
1
18
US
Carboxylesterase-expressing Allogeneic Neural Stem Cells, CE-secreting Allogeneic NSCs, hCE1m6-NSC, Irinotecan, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, U-101440E, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, Laboratory Biomarker Analysis, Pharmacological Study
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligoastrocytoma, Recurrent Anaplastic Oligodendroglioma, Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Malignant Glioma, Recurrent WHO Grade III Glioma
02/22
12/24
PIPAC, NCT04329494: for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

Recruiting
1
49
US
Biopsy, BIOPSY_TYPE, Bx, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Intraperitoneal Chemotherapy, Intraperitoneal Therapy, Irinotecan, Leucovorin, Folinic acid, Mitomycin, Ametycine, Jelmyto, MITO, Mito-C, Mito-Medac, Mitocin, Mitocin-C, Mitolem, Mitomycin C, Mitomycin-C, Mitomycin-X, Mitomycine C, Mitosol, Mitozytrex, Mutamycin, Mutamycine, NCI-C04706, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Malignant Uterine Neoplasm, Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Peritoneal Carcinomatosis, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Stage IV Appendix Carcinoma AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Appendix Carcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Appendix Carcinoma AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Stage IVC Appendix Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8
08/26
08/26
NYMC195, NCT04308330 / 2008-003800-73: Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

Recruiting
1
30
US
Vorinostat, Zolinza
New York Medical College
Ewing Sarcoma, Rhabdomyosarcoma, Wilms Tumor, Neuroblastoma, Hepatoblastoma, Germ Cell Tumor
12/23
12/24
NCT03290937: Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer

Active, not recruiting
1
42
US
Cetuximab, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U-101440E, Pharmacodynamic Study, PHARMACODYNAMIC, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
12/26
12/26
NCT03484299: Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Recruiting
1
20
US
Irreversible Electroporation (IRE), Gemcitabine, FOLFIRINOX
University of Louisville
Pancreas Cancer
12/23
07/24
RGX-202-001, NCT03597581: A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

Recruiting
1
108
US
ompenaclid, RGX-202-01, FOLFIRI, Bevacizumab, FOLFOX regimen
Inspirna, Inc.
Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Gastric Cancer, Gastric Neoplasm, KRAS Mutation-Related Tumors, CRC, Colorectal Cancer Metastatic
12/24
12/24
NCT04535401: Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

Active, not recruiting
1
10
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Diagnostic Imaging, Medical Imaging, Elimusertib, ATR Inhibitor BAY1895344, ATR Kinase Inhibitor BAY1895344, BAY 1895344, BAY-1895344, BAY1895344, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, CPT11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U 101440E, U-101440E, U101440E, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin
National Cancer Institute (NCI)
Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
03/24
04/25
NCT04920032: Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Recruiting
1
22
US
TAS-102, LONSURF, trifluoridine and tipiracil, Irinotecan, CAMPTOSAR, CPT-11, Standard Treatment, Signatera MRD ctDNA Assay
University of California, Irvine, Taiho Pharmaceutical Co., Ltd., Natera, Inc.
Colon Adenocarcinoma, Colorectal Cancer
12/24
12/25
NCT06156267: Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino

Not yet recruiting
1
30
RoW
Adebrelimab, mRNA tumor vaccines
Fudan University, Shanghai Regenelead Therapies Co., Ltd.
Pancreatic Cancer
04/26
03/27
MK-4280-001, NCT02720068: Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors

Completed
1
482
NA
Favezelimab, MK-4280, Pembrolizumab, MK-3475, KEYTRUDA®, Oxaliplatin, ELOXATIN®, Irinotecan, CAMPTOSAR®, Leucovorin (Calcium Folinate), WELLCOVORIN®, Fluorouracil [5-FU], ADRUCIL®, Favezelimab/Pembrolizumab, MK-4280A, Lenvatinib, E7080, MK-7902, LENVIMA®
Merck Sharp & Dohme LLC
Neoplasms
03/24
03/24
MV-0715-CP-001.01, NCT02672917: Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

Active, not recruiting
1
118
US
MVT-5873, HuMab-5B1, modified FOLFIRINOX (mFOLFIRINOX), gemcitabine + nab-paclitaxel
BioNTech Research & Development, Inc.
Pancreatic Cancer
08/24
10/26
ETCTN 10402, NCT04514497: Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Active, not recruiting
1
96
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Elimusertib, ATR Inhibitor BAY1895344, ATR Kinase Inhibitor BAY1895344, BAY 1895344, BAY-1895344, BAY1895344, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, CPT11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U 101440E, U-101440E, U101440E, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Topotecan Hydrochloride, Evotopin, Hycamptamine, Hycamtin, Nogitecan Hydrochloride, Potactasol, SKF S 104864 A, SKF S-104864-A, SKF S104864A, Topotec, Topotecan HCl, topotecan hydrochloride (oral)
National Cancer Institute (NCI)
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Neuroendocrine Carcinoma, Unresectable Pancreatic Adenocarcinoma
02/25
02/25
NCT05070104: CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Withdrawn
1
12
NA
CPI-613, Devimistat, modified FFX, Bevacizumab
Cornerstone Pharmaceuticals
C04.588.274.476.411.307
03/24
11/24
NCT01787500: Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Active, not recruiting
1
33
US
Cetuximab, Cetuximab Biosimilar CMAB009, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, U-101440E, Laboratory Biomarker Analysis, Pharmacological Study, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Genentech, Inc.
BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Neoplasm, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Unresectable Solid Neoplasm
03/26
03/26
NCT03854110: Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine

Recruiting
1
64
US
GP-2250, gemcitabine
Geistlich Pharma AG, Translational Drug Development
Pancreatic Cancer, Adult
09/24
12/24
NCT04641871: Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

Completed
1
78
Europe, Canada, US
Sym021, Anti-PD-1, Sym022, Anti-LAG-3, Sym023, Anti-TIM-3, Irinotecan Hydrochloride
Symphogen A/S
Metastatic Cancer, Solid Tumor
06/24
06/24
NCT03970252: Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

Completed
1
28
US
Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Irinotecan, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, U-101440E, Leucovorin, Folinic acid, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, citrovorum factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Therapeutic Conventional Surgery
Jonsson Comprehensive Cancer Center, Bristol-Myers Squibb, NovoCure Ltd.
Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
05/24
05/24
NCI 9938, NCT02595931: M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Active, not recruiting
1
66
US
Berzosertib, 2-Pyrazinamine, 3-(3-(4-((Methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)-, M 6620, M6620, VX 970, VX-970, VX970, Biopsy Specimen, Biopsy Sample, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, CPT11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U 101440E, U-101440E, U101440E
National Cancer Institute (NCI)
Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Carcinoma, Refractory Colorectal Carcinoma, Refractory Lung Small Cell Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Pancreatic Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Pancreatic Carcinoma
03/23
12/24
NCT05083780: Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer

Active, not recruiting
1
40
RoW
Chlorphenesin Carbamate, Hydroxychloroquine
Changhoon Yoo, Oncocross Co. Ltd., CytoGen, Inc.
Pancreatic Cancer
04/24
12/24
NCT06360354: A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion

Recruiting
1
188
US
AMG 193, Gemcitabine, Nab-paclitaxel, Modified FOLFIRINOX
Amgen
Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
11/25
11/27
NCT03189706: Study of Chemoimmunotherapy for High-Risk Neuroblastoma

Active, not recruiting
1
48
US
Irinotecan, temozolomide, Hu3F8, GM-CSF
Memorial Sloan Kettering Cancer Center, Y-mAbs Therapeutics
Neuroblastoma (NB)
06/25
06/25
ACT, NCT04021277: PS101-mediated With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin

Active, not recruiting
1
11
Europe
20 uL/kg PS101, 40 uL/kg PS101, Ultrasound
EXACT Therapeutics AS
Solid Tumor, Colorectal Cancer
09/24
09/24
NCT05320874: A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.

Not yet recruiting
1
232
RoW
KM257 Bispecific antibody
Xuanzhu Biopharmaceutical Co., Ltd.
Advanced Solid Tumor
06/24
11/26
NCT05084859: A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

Terminated
1
30
US, RoW
SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab
Biosplice Therapeutics, Inc.
Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Colorectal Cancer
10/22
10/22
NCT06396091: A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer

Recruiting
1
12
US
zolbetuximab, IMAB362, mFOLFIRINOX
Astellas Pharma Global Development, Inc.
Metastatic Pancreatic Adenocarcinoma
07/26
07/26
NCT01189643: Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor

Active, not recruiting
1
15
US
irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Sarcoma, Desmoplastic Small Round Cell Tumor (DSRCT)
08/25
08/25
NCT03715933: Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
240
US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx, Inc.
Solid Tumors, Malignant Pleural Mesothelioma, Gastric Adenocarcinoma, Colorectal Adenocarcinoma, Sarcoma, Pancreatic Adenocarcinoma, Ewing Sarcoma, Chondrosarcoma, GIST, SDH-deficient Solid Tumors
12/25
07/26
NCT03872947: A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Recruiting
1
187
Europe, US
TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD
Toray Industries, Inc
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
03/25
03/25
NL79619.078.21, NCT05379790: Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin

Recruiting
1
20
Europe
Irinotecan, Intraperitoneal irinotecan, CAPOX
Erasmus Medical Center
Gastric Cancer, Peritoneal Metastases
08/24
08/24
NX-1607-101, NCT05107674: A Study of NX-1607 in Adults With Advanced Malignancies

Recruiting
1
345
Europe, US
NX-1607, Cbl-b Inhibitor, Paclitaxel
Nurix Therapeutics, Inc.
Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma
08/24
02/26
NCT06586515: A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Not yet recruiting
1
530
NA
LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil
Eli Lilly and Company, Loxo Oncology, Inc.
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
03/29
03/29
DDRiver 511, NCT06509906: M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer

Not yet recruiting
1
54
Europe, Japan, US, RoW
M9466, HRS-1167, Irinotecan, Folinic acid, Calcium folinate Leucovorin, Fluorouracil (5-FU), 5-FU, Bevacizumab
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Advanced Solid Tumor
04/26
04/26
NCT06278454: Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC)

Not yet recruiting
1
58
RoW
NRT6008 Injection + Systematic chemotherapy, Investigational Product + Systematic chemotherapy
Chengdu New Radiomedicine Technology Co. LTD.
Unresectable Pancreatic Cancer
12/26
12/26
NCT06607185: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Not yet recruiting
1
750
NA
LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Eli Lilly and Company
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
01/30
01/30
LAP-NET1, NCT05546853: Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

Recruiting
1
52
Europe
NP137, Oxaliplatin, Irinotecan, Calcium levofolinate, 5 FU
University Hospital, Grenoble, NETRIS Pharma
Pancreatic Ductal Adenocarcinoma
03/26
03/27
NCT04161755: Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery

Active, not recruiting
1
29
US
Atezolizumab, RO7198457, mFOLFIRINOX
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Pancreatic Cancer
11/24
11/24
NCT04239092: 9-ING-41 in Pediatric Patients With Refractory Malignancies.

Recruiting
1
68
US
9-ING-41, 9-ING-41 COMPOUND, Irinotecan, CPT-11, Temozolomide, Temodar, Cyclophosphamide, Cyclophosphamide IV, Topotecan, Topotecan IV
Actuate Therapeutics Inc.
Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma
12/24
12/24
NCT05417386: FOLFIRINOX + NIS793 in Pancreatic Cancer

Terminated
1
4
US
FOLFIRINOX, Oxaliplatin, Eloxatin, Leucovorin, Calcium Leucovorin, Citrovorum Factor, Folinic Acid, Irinotecan, Camptosar, Camptothecin-11, CPT-1, 5-Fluorouracil (5-FU), Adrucil, NIS793, Chemoradiation, Capecitabine, Xeloda, Radiation Therapy, Surgery
Colin D. Weekes, M.D., PhD, Novartis
Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
07/23
07/23
NCI-2015-00693, NCT02419495: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies

Terminated
1
221
US
Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Eribulin, ER-086526, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U-101440E, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio, Topotecan, Hycamptamine, Topotecan Lactone
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC V8, Clinical Stage IV Cutaneous Melanoma AJCC V8, Fallopian Tube Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Ovarian Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC V8, Pathologic Stage IIIA Cutaneous Melanoma AJCC V8, Pathologic Stage IIIB Cutaneous Melanoma AJCC V8, Pathologic Stage IIIC Cutaneous Melanoma AJCC V8, Pathologic Stage IIID Cutaneous Melanoma AJCC V8, Pathologic Stage IV Cutaneous Melanoma AJCC V8, Primary Peritoneal Carcinoma, Stage III Lung Cancer AJCC V8, Stage III Renal Cell Cancer AJCC V8, Stage IIIA Lung Cancer AJCC V8, Stage IIIB Lung Cancer AJCC V8, Stage IIIC Lung Cancer AJCC V8, Stage IV Lung Cancer AJCC V8, Stage IV Renal Cell Cancer AJCC V8, Stage IVA Lung Cancer AJCC V8, Stage IVB Lung Cancer AJCC V8, Triple-Negative Breast Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Unresectable Renal Cell Carcinoma
09/24
09/24
STARLING, NCT05576077: A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

Recruiting
1
60
Canada, US
TBio-4101, TIL, autologous, tumor-reactive, T-cell product, Pembrolizumab, Keytruda
Turnstone Biologics, Corp.
Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
12/24
06/25
NCT04199026: Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Not yet recruiting
1
20
US
Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Drug Delivery Microdevice, Microdevice, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Ganitumab, AMG 479, Anti-IGF-1R Human Monoclonal Antibody AMG-479, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Irinotecan, Pazopanib, GW786034, Polyethylene Glycol, Glycol, polyethylene, PEG, Poly(oxyethylene), Polyethylene Glycol 400, Polyethylene Glycol 8000, POLYETHYLENE GLYCOL, UNSPECIFIED, Polyethylene Oxide, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel, Therapeutic Conventional Surgery, Vincristine, LEUROCRISTINE, VCR, Vincrystine
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma
12/25
12/25
NCT06203821: Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer

Not yet recruiting
1
25
US
NP137
Nabeel Badri, NETRIS Pharma
Pancreatic Cancer
12/27
12/27
NCT04862260: Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

Active, not recruiting
1
3
Canada
Cholesterol metabolism disruption, A combination of a lipophilic statin (Atorvastatin, Lipitor), a NPC1L1 inhibitor (Ezetimibe, Ezetrol) and a PCSK9 inhibitor (Evolocumab, Repatha) with chemotherapy in pancreatic cancer
CHU de Quebec-Universite Laval, Canadian Institutes of Health Research (CIHR), Biovalorem
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreas Cancer, Metastatic Cancer
01/25
12/26
I-FLOAT, NCT04361708: Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

Recruiting
1
54
US
Oxaliplatin, Docetaxel, Leucovorin, Irinotecan, 5-Fluorouracil
University of Chicago
Pancreatic Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Adenocarcinoma
06/25
05/27
NCT04808323: MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer

Recruiting
1
22
US
Capecitabine, Xeloda, Initial Dose of Radiation before Dose Escalation, Cohort A: Dose Escalation Radiation, Cohort B: Dose Escalation Radiation, Cohort C: Dose Escalation Radiation, FOLFOX, Oxaliplatin de Gramont, OxMdG
Medical College of Wisconsin
Rectal Adenocarcinoma
06/25
06/26
NCT05722327: Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

Recruiting
1
24
US
MRTX849, Irinotecan, Cetuximab, C225, Erbitux™, MC-C225, MOAB C225
M.D. Anderson Cancer Center, Mirati Therapeutics
Colon Cancer, Colorectal Cancer
09/25
09/27
Intrinsic, NCT04929223: A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Recruiting
1
422
Europe, Canada, US, RoW
Inavolisib, Bevacizumab, Avastin, Cetuximab, Atezolizumab, Tecentriq, Tiragolumab, SY-5609, Divarasib, GDC-6036, FOLFOX, FOLFIRI
Hoffmann-La Roche
Metastatic Colorectal Cancer
09/25
04/26
NCT06011772: EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Recruiting
1
42
US
Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine, Cimavax, CIMAvax EGF, Epidermal Growth Factor (EGF) Vaccine, Leucovorin, Oxaliplatin, Fluorouracil, Bevacizumab, Irinotecan, Cetuximab, Metastasectomy, Biospecimen collection, Computed Tomography, CAT, CAT SCAN, Panitumumbab, ABX-EGF, ABX-EGF Monoclonal Antibody
Roswell Park Cancer Institute
Colo-rectal Cancer
12/25
12/26
Aflac-NBL-2002, NCT05400603: Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma

Recruiting
1
24
US
Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate
Emory University
Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma, Relapsed Osteosarcoma, Refractory Osteosarcoma
12/25
12/25
NCT05365581: A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Recruiting
1
305
Europe, Japan, US, RoW
ASP2138, Pembrolizumab, Oxaliplatin, Leucovorin, Folinic acid, Fluorouracil, Ramucirumab, Paclitaxel, Irinotecan
Astellas Pharma Global Development, Inc.
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
10/26
04/27
RANT-GC, NCT05733689: Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers ( Trial)

Not yet recruiting
1
20
US
ctDNA Blood Test, FLOT, FOLFOX, FOLFIRI, FOLFIRINOX, PACLITAXEL with or without CARBOPLATIN, DOCETAXEL and IRINOTECAN (alone or combined), NIVOLUMAB (alone or when added to a regimen above), PEMBROLIZUMAB (alone or when added to a regimen above)
University of California, Irvine, Natera, Inc.
Gastroesophageal Adenocarcinoma
02/26
02/26
NCT05669339: AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma

Recruiting
1
12
US
Irinotecan, Sonidegib, Sorafenib
University of Florida, Sun Pharmaceutical Industries Ltd
Hepatocellular Carcinoma
04/26
04/26
ACT, NCT05238831: SMMART Adaptive Clinical Treatment () Trial

Withdrawn
1
25
NA
Alectinib, AF-802, AF802, Alecensa, ALK Inhibitor RO5424802, CH5424802, RG7853, RO5424802, Alpelisib, BYL719, Phosphoinositide 3-kinase Inhibitor BYL719, Piqray, VIJOICE, Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Zirabev, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Entrectinib, Rozlytrek, RXDX 101, RXDX-101, RXDX101, Eribulin, ER-086526, Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ZD9238, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, Phesgo, Irinotecan, Letrozole, CGS 20267, Femara, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Niraparib, MK-4827, MK4827, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Pertuzumab, 2C4, 2C4 Antibody, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, Quality-of-Life Assessment, Quality of Life Assessment, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf, Vinorelbine, Dihydroxydeoxynorvinkaleukoblastine, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449
OHSU Knight Cancer Institute, Genentech, Inc., Oregon Health and Science University
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
05/26
05/26
NCT05848739: A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Recruiting
1
130
US
ST316, FOLFIRI regimen & bevacizumab, FOLFIRI, Fruquintinib, Lonsurf & bevacizumab
Sapience Therapeutics
Colon Cancer, Metastatic Colon Cancer
05/26
05/27
CodeBreak101, NCT04185883: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Checkmark Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Sep 2022 - Sep 2022: Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Checkmark Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Checkmark Results from CodeBreak 101 study in combination with RMC-4630 at IASLC-WCLC
More
Recruiting
1
1200
Europe, Canada, Japan, US, RoW
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Amgen
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
09/25
03/28
MINOTAUR, NCT05147350: Study of RP-6306 With FOLFIRI in Advanced Solid Tumors

Active, not recruiting
1
36
Europe, Canada, US
RP-6306 (oral PKMYT1 inhibitor), FOLFIRI
Repare Therapeutics
Advanced Solid Tumor
07/26
11/26
NCT05838768: Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

Recruiting
1
327
Europe, Japan, US, RoW
HRO761, pembrolizumab, irinotecan
Novartis Pharmaceuticals
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
01/30
01/30
IGM-8444-001, NCT04553692: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers

Active, not recruiting
1
272
Europe, US, RoW
Aplitabart (IGM-8444), FOLFIRI, Fluorouracil or 5-FU, Leucovorin, Irinotecan, Bevacizumab (and approved biosimilars), Avastin, Birinapant, Venetoclax, Venclexta, Gemcitabine, Gemzar, Docetaxel, Taxotere, Docefrez, Azacitidine, VIDAZA
IGM Biosciences, Inc.
Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
06/26
08/27
PRAAR1, NCT05912075: Preoperative Radiotherapy And ASTX660 in Rectum Cancer

Recruiting
1
78
Europe
mFOLFIRINOX, Pelvic radiotherapy LCRT, Capecitabine, TOLINAPANT (ASTX660), Pelvic radiotherapy SCRT, FOLFOX4, CAPOX, Capecitabine + Oxaliplatine
Gustave Roussy, Cancer Campus, Grand Paris
Locally-advanced Rectal Cancer
01/28
01/29
NCT05694715: Combination Therapy in Cancers With Mutations in DNA Repair Genes

Recruiting
1
24
US
Niraparib, Zejula, Small molecule inhibitor, Irinotecan, Camptosar, Irinotecan hydrochloride, CPT-11
University of California, San Francisco, GlaxoSmithKline
Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation, ATM Gene Mutation, PALB2 Gene Mutation
01/28
01/28
 

Download Options